Because revumenib disrupts the effect of epigenetic regulators in leukaemia that are dependent on the menin–KMT2A interaction, this leads to abrogation of aberrant gene expression and removal of the haematopoietic differentiation block12,13. The gene discussed is KMT2A; the disease is leukemia.